Apollomics Statistics
Total Valuation
Apollomics has a market cap or net worth of $38.43 million. The enterprise value is $33.38 million.
| Market Cap | 38.43M |
| Enterprise Value | 33.38M |
Important Dates
The last earnings date was Monday, April 27, 2026, before market open.
| Earnings Date | Apr 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Apollomics has 2.20 million shares outstanding. The number of shares has increased by 41.77% in one year.
| Current Share Class | 2.20M |
| Shares Outstanding | 2.20M |
| Shares Change (YoY) | +41.77% |
| Shares Change (QoQ) | +62.18% |
| Owned by Insiders (%) | 42.62% |
| Owned by Institutions (%) | 4.67% |
| Float | 1.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.07 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.96
| Current Ratio | 0.96 |
| Quick Ratio | 0.91 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -140.48 |
Financial Efficiency
Return on equity (ROE) is -1,305.37% and return on invested capital (ROIC) is -347.45%.
| Return on Equity (ROE) | -1,305.37% |
| Return on Assets (ROA) | -57.61% |
| Return on Invested Capital (ROIC) | -347.45% |
| Return on Capital Employed (ROCE) | -2,353.35% |
| Weighted Average Cost of Capital (WACC) | 12.56% |
| Revenue Per Employee | $631,571 |
| Profits Per Employee | -$781,357 |
| Employee Count | 14 |
| Asset Turnover | 0.89 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Apollomics has paid $3,000 in taxes.
| Income Tax | 3,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +175.34% in the last 52 weeks. The beta is 1.53, so Apollomics's price volatility has been higher than the market average.
| Beta (5Y) | 1.53 |
| 52-Week Price Change | +175.34% |
| 50-Day Moving Average | 14.30 |
| 200-Day Moving Average | 15.67 |
| Relative Strength Index (RSI) | 68.78 |
| Average Volume (20 Days) | 12,611 |
Short Selling Information
The latest short interest is 1,592, so 0.07% of the outstanding shares have been sold short.
| Short Interest | 1,592 |
| Short Previous Month | 3,260 |
| Short % of Shares Out | 0.07% |
| Short % of Float | 0.13% |
| Short Ratio (days to cover) | 0.20 |
Income Statement
In the last 12 months, Apollomics had revenue of $8.84 million and -$10.94 million in losses. Loss per share was -$7.57.
| Revenue | 8.84M |
| Gross Profit | 8.84M |
| Operating Income | -9.13M |
| Pretax Income | -10.94M |
| Net Income | -10.94M |
| EBITDA | -9.09M |
| EBIT | -9.13M |
| Loss Per Share | -$7.57 |
Balance Sheet
The company has $3.28 million in cash and $643,000 in debt, with a net cash position of $2.63 million or $1.20 per share.
| Cash & Cash Equivalents | 3.28M |
| Total Debt | 643,000 |
| Net Cash | 2.63M |
| Net Cash Per Share | $1.20 |
| Equity (Book Value) | -3.19M |
| Book Value Per Share | -1.48 |
| Working Capital | -275,000 |
Cash Flow
| Operating Cash Flow | -10.37M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 46,000 |
| Net Borrowing | -125,000 |
| Free Cash Flow | -10.37M |
| FCF Per Share | -$4.72 |
Margins
Gross margin is 100.00%, with operating and profit margins of -103.27% and -123.72%.
| Gross Margin | 100.00% |
| Operating Margin | -103.27% |
| Pretax Margin | -123.68% |
| Profit Margin | -123.72% |
| EBITDA Margin | -102.75% |
| EBIT Margin | -103.27% |
| FCF Margin | n/a |
Dividends & Yields
Apollomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -41.77% |
| Shareholder Yield | -41.77% |
| Earnings Yield | -30.37% |
| FCF Yield | -28.79% |
Analyst Forecast
The average price target for Apollomics is $200.00, which is 1,042.99% higher than the current price. The consensus rating is "Buy".
| Price Target | $200.00 |
| Price Target Difference | 1,042.99% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (3Y) | 13.12% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 25, 2024. It was a reverse split with a ratio of 1:100.
| Last Split Date | Nov 25, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
Apollomics has an Altman Z-Score of -150.7 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -150.7 |
| Piotroski F-Score | 2 |